The Big Health Care Conundrum: How To Sustainably Unlock The Value Of Diagnostics
Novo Holdings Panel Asks Diagnostics Industry Leaders How To Keep The Focus On Testing Post-Pandemic
Executive Summary
With COVID-19 a residual but still very real issue globally, Novo Holdings asked the big diagnostics question at a recent high-level roundtable: How can stakeholders capitalize on this moment of acute public awareness of diagnostics to improve adoption of tests and screening in the long term? The CEOs of Roche Diagnostics, GE Healthcare, Labcorp and Synlab, among others, gave their thoughts on how the system must change.
You may also be interested in...
Epic Sciences Talks Differentiation And Benefits Of Its DefineMBC Cancer Test
Epic Sciences spoke to Medtech Insight to discuss the development of its DefineMBC test for metastatic breast cancer.
Putting The E In ESG: A Global Medtech’s Approach To Meeting The Climate Challenge
The pressures on global medtechs to focus more on sustainability are internal as well as external. Scope 3 adds yet another layer of compliance. Johnson & Johnson’s EMEA VP for Surgical Vision Erin McEachren explains to In Vivo how her organization meets these challenges while simultaneously addressing EU Medical Device Regulation requirements and ensuring patient safety standards.
Putting The E In ESG: The Provider’s View Of Sustainability Compliance
As the health care sector moves from linear to circular, medtechs, providers and patients all have roles to play in ensuring that current strategies, practices and behaviors contribute to guarantee a sustainable future. Part one of a short series on this theme looks as best practice for providers.